

April 30, 2014

Ono Pharmaceutical Co., Ltd.  
Nissan Chemical Industries, Ltd

### Discontinuation of the license agreement for a new therapeutic agent for thrombocytopenia

Nissan Chemical Industries, Ltd. (Tokyo, Japan, President: Kojiro Kinoshita, "Nissan") and Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President, Representative Director, and CEO: Gyo Sagara, "Ono") announced today that both companies agreed to terminate the license agreement for a new therapeutic agent for thrombocytopenia effective on April 30, 2014.

Ono has been granted the worldwide exclusive rights to develop and to commercialize the compound (NIP-022/ONO-7746) from Nissan since 2007. NIP-022/ONO-7746 demonstrated good safety, well tolerability and a potent platelet increasing effect in the phase 1 clinical trial for healthy individuals. While Ono had conducted further clinical trial in cancer patients with chemotherapy induced thrombocytopenia, Ono decided to discontinue the development of the compound on Ono's strategic grounds.

Ono returns to Nissan all rights granted under the license agreement in connection with its termination, including granting to Nissan exclusive rights to use all of the non-clinical and clinical data developed by Ono. After the discontinuation, without any restriction Nissan can continue to develop and commercialize the compound on a worldwide basis, including collaboration with a potential partner in the future.

#### About thrombocytopenia

Platelets are one of blood cell components and play an important role in hemostasis upon bleeding. For instance, hematological disorders such as idiopathic thrombocytopenic purpura, aplastic anemia and myelodysplastic syndromes are associated with the decrease of platelet count or thrombocytopenia often causing bleeding, which is life-threatening in severe cases.

Thrombocytopenia is also found during cancer chemotherapy, chronic liver disease and the treatment of hepatitis C and may impair the treatment of those diseases.

#### About NIP-022/ONO-7746

NIP-022/ONO-7746 is an orally active small molecule compound discovered by Nissan, which may increase platelet count by activating a receptor of thrombopoietin to accelerate platelet production.